Alder BioPharmaceuticals® to Host Conference Call to Discuss First Quarter 2019 Financial and Operating Results
April 26, 2019 16:05 ET
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., April 26, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 26, 2019 16:05 ET
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., April 26, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (Nasdaq: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
Alder BioPharmaceuticals® to Present New Analyses of Eptinezumab’s Clinical Trial Data Describing Early, Robust Migraine Prevention and Quality of Life Impact at 2019 American Academy of Neurology Annual Meeting
April 23, 2019 08:00 ET
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., April 23, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
U.S. Food and Drug Administration Accepts Biologics License Application for Eptinezumab
April 22, 2019 16:34 ET
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., April 22, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 19, 2019 16:19 ET
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., April 19, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (Nasdaq: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 12, 2019 16:05 ET
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., April 12, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
Alder BioPharmaceuticals® Appoints Nadia Dac as Chief Commercial Officer
April 08, 2019 16:05 ET
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., April 08, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
Alder BioPharmaceuticals® to Present at the 18th Annual Needham Healthcare Conference
April 02, 2019 08:00 ET
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., April 02, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
Alder BioPharmaceuticals® to Present at the Cowen and Company 39th Annual Health Care Conference
March 05, 2019 08:00 ET
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash, March 05, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
Alder BioPharmaceuticals, Inc. Announces Closing of Public Offering and Private Placement of Common Stock and Exercise in Full of Option to Purchase Additional Shares
March 04, 2019 18:48 ET
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., March 04, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...